A comprehensive view of Galecto, Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Galecto completes enrollment for Phase 2b trial of inhaled GB0139 galectin-3 inhibitor for idiopathic pulmonary fibrosis delivered by generic dry powder inhaler; about 100,000 patients in US affected by IPF
Published: May 09, 2022 by GlobeNewswire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count